Please use this link to access this publication. Abstract Cohort studies and meta-analyses have documented a robust association between cannabis use, heavy use, and misuse with future risk of schizophrenia….
Condition: Schizophrenia
The relationship between cannabis and schizophrenia: a genetically informed perspective
Please use this link to access this publication. Abstract Background and Aims While epidemiological studies support a role for heavy, high-potency cannabis use on first-episode psychosis, genetic models of causation…
When Cannabis Use Goes Wrong: Mental Health Side Effects of Cannabis Use That Present to Emergency Services
Abstract Cannabis use is a modifiable risk factor for the development and exacerbation of mental illness. The strongest evidence of risk is for the development of a psychotic disorder, associated…
Changes in Incident Schizophrenia Diagnoses Associated With Cannabis Use Disorder After Cannabis Legalization
Key Points Question Were the liberalization of medical cannabis and the legalization of nonmedical cannabis in Canada associated with changes in the population-attributable fraction of cannabis use disorders associated with schizophrenia?…
Perceptions and engagement of patients with chronic conditions on the use of medical cannabis: a scoping review
Abstract Context Studies generally focus on one type of chronic condition and the effect of medical cannabis (MC) on symptoms; little is known about the perceptions and engagement of patients…
Randomized Laboratory Study of Single-Dose Cannabis, Dronabinol, and Placebo in Patients With Schizophrenia and Cannabis Use Disorder Get access Arrow
Please use this link to access this publication. Abstract Background and Hypothesis Up to 43% of people with schizophrenia have a lifetime cannabis use disorder (CUD). Tetrahydrocannabinol (THC) has been…
Cannabis with high cannabidiol content is associated with fewer psychotic experiences
Abstract Objective Cannabis is associated with psychotic outcomes in numerous studies, an effect that is commonly attributed to Δ 9-tetrahydrocannabinol (Δ 9-THC). An increasing number of authors identify cannabidiol, another component…
THC and endocannabinoids differentially regulate neuronal activity in the prefrontal cortex and hippocampus in the subchronic PCP model of schizophrenia
Please use this link to access this publication. Abstract Cannabis use has been associated with an increased risk to develop schizophrenia as well as symptom exacerbation in patients. In contrast,…
A systematic review of the effect of cannabidiol on cognitive function: Relevance to schizophrenia
Please use this link to access this publication. Abstract Background and objectives Cognitive impairment is a core symptom domain of schizophrenia, neurological disorders and substance abuse. It is characterised by deficits in learning,…
Individual and combined effects of acute delta-9-tetrahydrocannabinol and cannabidiol on psychotomimetic symptoms and memory function
Abstract The main active ingredient in cannabis, delta-9-tetrahydrocannabinol (THC), can acutely induce psychotic symptoms and impair episodic and working memory. Another major constituent, cannabidiol (CBD), may attenuate these effects. This…